Regeneron Pharmaceuticals Inc vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $213.44 (market cap $39.15B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 111 Days on average.
| REGN | TTWO | |
|---|---|---|
Market Cap | $76.14B | $39.15B |
Volume | 500,239 | 2,708,429 |
Sector | Health | Technology |
52-Week High | $852.03 | $262.29 |
52-Week Low | $557.73 | $189.69 |
Typical Hold Time | 107 Days | 111 Days |
Enterprise Value | $70.85B | $40.27B |
Dividend Yield | 0.51% | — |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
Take-Two Interactive (TTWO) trades at $209.37, up 2.63% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q4 2025 and Q1 2026 but missing in Q2 2026, while the company reaffirmed the GTA VI launch date for November 19, 2026. Financials reveal negative net income margins and elevated debt levels, though revenue growth is projected to $6.7B in 2026. The stock is near its pivot point of $209, with support at $206 and resistance at $212.
The outlook hinges on GTA VI's successful launch driving revenue growth and profitability improvements. Risks include execution challenges, competitive pressures, and high valuation multiples. Analyst optimism, with a $292.30 price target, suggests significant upside if operational targets are met, but investors must weigh near-term losses against long-term game release catalysts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →